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GUEST EDITORIAL
Modern clinical practice commonly deals
with the complications of atherosclerosis
both in acute and potentially life-threaten-
ing and severely debilitating manifesta-
tions,and in chronic manifestations that
may result in marked impairment of exer-
cise and working capacity. Epidemiolo-
gical information and intervention with
drugs clearly indicate that atherosclerosis
can be limited. Plasma lipids have been
implicated in the pathogenesis of athero-
sclerosis,with variable strength of associa-
tion: severe metabolic errors increasing
risk profoundly while ‘moderate’ hyperc-
holesterolaemia and low concentrations of
high-density lipoprotein in concert with
other risk factors can also signify a high
risk. Other clinical problems linked with
errors in lipid and lipoprotein metabolism
include pancreatitis, malabsorption and
many other rarer syndromes.
The developments in biochemistry and,
more recently, in genetics have made it
possible to understand better the normal
metabolism and the mechanisms of dis-
ease.While insights into cell biology have
also made the pathology easier to under-
stand,complications of these disorders are
still not fully predictable. Information has
become widely available to the lay person,
who expects the medical practitioner to
have a broad knowledge and to make an
exact diagnosis. This issue of CME will
update the practitioner on recent develop-
ments.
In the first article there is a description of
normal metabolism followed by a system-
atic classification of the different metabol-
ic errors that are known to date.The
monogenic disorders described vary from
common (about 1% of the population) to
rare but all have phenotypes that should
be recognisable through understanding of
metabolism and a good clinical approach.
The clinical approach described by Blom
and Firth revisits essential features in the
history and examination of the patient. In
keeping with modern trends, these
authors demonstrate the importance of
evaluating the risk of a myocardial infarc-
tion as the basis for initiating treatment.
As indicated by Maritz, secondary dyslipi-
daemia should always be considered and
specifically excluded before ascribing the
dyslipidaemia to environmental and
genetic interactions.The importance of
the metabolic syndrome seen as part of
overnutrition and unfavourable lifestyle
cannot be over-emphasised.The chapter
on laboratory tests for dyslipidaemia by
Vermaak gives practical information about
investigations but still emphasises the
need for a global risk assessment.
Raal deals with therapeutic strategies that
in conjunction with lifestyle changes will
best reduce cardiovascular risk.The sec-
tion on genetics indicates the state-of-the-
art investigation that is available in South
Africa, a country known for its high
prevalence of genetic disorders.The rich
heritage of immigrant communities has
resulted in several founder effects. Other
genes are known to influence the risk of
atherosclerosis in the monogenic and
polygenic and even mild dyslipidaemias.
The dietetic advice given by Fuller may
seem strict to many medical practitioner s
and patients. It assumes that there is sig-
nificant risk for the patient and that there
is a sincere attempt to lower the risk dra-
matically. It describes food composition as
this is the foundation on which the
recommendations are built. Recipes
remain to be adapted and implemented
by the patient, who may benefit from fur-
ther assistance from dietitians so that
appropriate foodstuffs may be selected
and prepared for enjoyment and health.
One of the most active figures in the dys-
lipidaemias of South Africa,Harry Seftel,
relates how insight into dyslipidaemia and
atherosclerosis developed in this countr y
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over the past half centur y. Seftel indeed contributed to
and experienced the results of dedicated medical and
scientific colleagues who received meaningful suppor t
for research. Sadly, the support for clinical and labora-
tory expertise has dwindled at a time that the rest of
the world has seen a rise in preventive practice with
the modern era of successful, expensive but cost-effec-
tive pharmaceutical and technological intervention.
While the interventional strategies are simple and can
be delegated to a wide range of medical practitioners,
the monogenic disorders of lipid metabolism abound
in this country and require the expertise that is now
available (and under threat) at a few lipid clinics in
teaching hospitals.
Cardiovascular disease is the most important cause of
mortality and morbidity in developed countries and is
predicted to assume the same prominence in develop-
ing countries by 2020.Where does the responsibility
for preventing cardiovascular disease lie? The responsi-
bility is divided between the individual, the medical
practitioner and the organisation that interfaces
between the providers of health care and individuals.
Each individual can significantly reduce the risk of ath-
erosclerosis by adopting a healthy lifestyle: refraining
from smoking, exercising regularly, following a low-fat
diet rich in plant and marine foods, and not becoming
obese. Education will also help to recognise risk fac-
tors for atherosclerosis, including a family history of
complications of atherosclerosis, severe dyslipidaemia,
hypertension and diabetes. Most importantly, in mod-
ern society the individual should prepare for future
medical expenses and be compliant with management.
The medical practitioner should detect risk early and
evaluate each patient for the global risk of atheroscle-
rosis.The medical practitioner should also ensure that
the patient has adopted an appropriate diet and
lifestyle;drugs should be prescribed judiciously but in
keeping with recommendations based on developments
in research.Organisations, whether as part of govern-
ment or private health service, have a responsibility to
emphasise and support preventive measures against
atherosclerosis. Already these organisations are begin-
ning to introduce incentives and perform surveillance
for compliance.The appropriateness of prescription
medicine and controlling its cost is not the only way
for these organisations to ensure the best management
for their dependants — there is room for accountabili-
ty and efficiency in their management as well.
There is still a great need for research before athero-
sclerosis can be conquered. Improvements in the pre-
diction of cardiovascular events may come with better
collation of data pertaining to risk and from surveil-
lance of changes in markers for risk such as inflamma-
tory markers,and imaging of vessels. Intervention with
modern lipid-modifying drugs offers the most appro-
priate interception for severe dyslipidaemias but is par-
tially successful for reducing risk of atherosclerosis in
general.Future research may identify treatable forms
of predisposition to the complications of atherosclero-
sis that fall in the realms of haemostasis, inflammation,
tissue properties and repair, as well as other processes
or genes that may be modulated.It is also hoped that
treatment and technology will become more afford-
able.
SINGLE SUTURE
Tobacco companies’ workaround on film
advertising
There is a minor revolution taking place in film
advertising.Instead of companies spending pots
of money on producing, distributing and paying
for their ads to be shown on cinema screens,
advertising moguls have cottoned on to the fact
that they could quite easily let the movie industry
do it for them. So if you keep your eyes open
when next you go to a movie, you will see only
certain brands of cars,fizzy drinks,liquors and
clothes being shown on screen. But it goes
against the spirit (but maybe not the letter) of the
law, when this applies to tobacco advertising.The
BMJ News Roundup (2002; 324: 190) reports
that a San Francisco group calling themselves
Smoke Free Movies, is complaining about the
fact that actress Sissy Spacek not only chain
smokes but also ‘broods over a Marlboro pack’
and specifically asks for ‘Marlboro Lights’ in the
movie In the Bedroom. Insidiously, slowly and
almost without being noticed, smoking in movies
is making a comeback despite assurances from
the industry to the US Congress.The lead char-
acter in Training Day played by Denzel
Washington is also seldom to be seen without a
cigarette in his mouth, but at least the brand is
not that obvious.
